Sodium-glucose co-transporter-2 inhibitors are a novel class of hypoglycemic agents recommended for type 2 diabetic patients with DKD by a group of guidelines, and a clinical study showed that the use of SGLT2 inhibitors could significantly reduce the level of sd-LDL-C in patients with T2D (36). The gene discussed is SLC5A2; the disease is diabetic kidney disease.